May 23 (Reuters) - Health tech firm Medtronic ( MDT )

beat Wall Street estimates for quarterly profit and revenue on

Thursday, as a pickup in surgical volumes at hospitals lifted

demand for its medical devices.

Investor expectations around the financial performance of

medical devices makers have grown lately, owing to a resurgence

in demand as people, especially older adults, opted for medical

procedures deferred during the COVID-19 pandemic.

Medtronic ( MDT ) forecasts fiscal 2025 adjusted per-share profit in

the range of $5.40 to $5.50, with its midpoint in line with

analysts' average estimate of $5.45, according to LSEG data.

The Dublin-based company joins medical device makers such as

Abbott Laboratories ( ABT ) and Boston Scientific ( BSX ) that

have also benefited from soaring demand for non-urgent

surgeries.

The company took an adjusted charge of $439 million in the

fourth quarter, higher than its previously disclosed estimate of

between $350 million and $425 million, related to its decision

to exit its unprofitable ventilator product line and reorganize

the respiratory and patient monitoring businesses.

Sales at the company's diabetes unit, which returned to

growth in the U.S. last quarter, rose 10.9% in the quarter ended

April 26.

However, sales at Medtronic's ( MDT ) heart devices unit, its

biggest revenue driver, fell 5.2% to $3.13 billion, missing

analysts' estimate of $3.14 billion.

Its second-biggest unit by revenue, neuroscience, which

makes medical devices and implants used in the treatment of the

spine and musculoskeletal system, posted a 5.6% rise in sales,

topping analysts' expectations.

The medical technology firm's total revenue of $8.59 billion

beat analysts' average estimate of $8.44 billion.

It posted adjusted profit of $1.46 per share for the fourth

quarter, compared with the $1.45 per share estimated.